FMA
PBYI icon

FNY Managed Accounts’s Puma Biotechnology PBYI Stock Holding History

FNY Managed Accounts’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,000
Closed -$117K – 378
2016
Q1 		$117K Buy
+4,000
New +$181K 0.21% 87

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

FNY Managed Accounts's PBYI Position: Q2 2016 in Review

FNY Managed Accounts sold out of Puma Biotechnology (PBYI) in Q2 2016, closing a stake of 4,000 shares — an estimated $117K sold.

FNY Managed Accounts first reported a position in PBYI in Q1 2016 and held it in 1 quarter. The position peaked at $117K in Q1 2016. 110 funds tracked by Wall St. Rank hold PBYI as of Q2 2016.

  • FNY Managed Accounts reported no remaining Puma Biotechnology position as of Q2 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 4,000 Puma Biotechnology shares in Q2 2016, an estimated $117K.
  • FNY Managed Accounts first reported a position in Puma Biotechnology in Q1 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Puma Biotechnology position peaked at $117K in Q1 2016.
  • 110 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2016.

Based on FNY Managed Accounts's 13F filing for Q2 2016, filed 27 Jul 2016.